Canada, are often granting market access on the basis of efficacy data alone. Because of this lack of effectiveness data, information is mostly extrapolated from the existing efficacy data. In theory it should be left to evidence-based-medicine specialists to estimate this information. In practise this is done as an integral part of most economic evaluations. We challenge this practise and propose to separate the estimation of effectiveness from the overall process of economic evaluations. Our main argument is that the estimation of effectiveness is not necessarily a core competency for authors of economic evaluations. RESULTS: Hence this crucial issue gets too little attention in discussions and guidelines of economic evaluations. Subsequently we argue that this niche of evidence-based-medicine is still underdeveloped. It urgently needs scientific discussion and development of its own guidelines. CONCLUSIONS: We propose that the estimation of effectiveness on the basis of efficacy data should be done as an endeavour in itself. This would make the appraisal of these two distinct procedures, namely effectiveness assessment and economic evaluation, clearer and thus more valuable. The European Union is currently trying to develop this field (Pharmaceutical Forum Conclusions-Press release September 29, 2006). 3 Quintiles Research Group, Irene, Gauteng Province, South Africa OBJECTIVES: Pharmacoeconomics (PE) has been defined as 'the description and analysis of costs of drug therapy to health care systems and society'. PE concepts and methods have been with us since the early seventies. The trend in the use of PE in formulary decision-making, disease management programmes and cost-effectiveness of health care interventions is on the increase. This study investigated the role of PE in decision-making in the private and public sectors of the health care system in the Gauteng region. METHODS: Two focus group sessions were conducted at Technikon Pretoria. Face-to-face interviews were also conducted with key informants in PE who did not participate in both focus groups. The triangulation method of combining focus group methods and face-to face interviews was chosen to increase the reliability of the data. Six and three participants for the first and second focus groups, respectively, with similar backgrounds in PE were recruited from both the private and public sectors. A moderator who was conversant in PE facilitated the focus group sessions while the researcher recorded the responses from the participants. RESULTS: Using the Donabedian matrix for the analysis, mixed results were observed in the private and public sectors about the perception and use of PE. There was an increased awareness of PE as a decision-making tool by most respondents. Lack of PE culture, conflict of interest, and wastage of resources were the most prevalent health care concerns affecting both sectors of the health care system of the Province. Although PE methods are globally transferable, models are required to reflect the Gauteng Province's health care setting. CONCLUSION: PE exists as a decision-making tool aimed at demonstrating the value for money in the allocation of health care resources. PE is instrumental in understanding and solving the health care issues faced by decision makers both sectors of the health care system in the Gauteng Province. To use item response theory (i.e. Rasch) analysis to develop and evaluate scales to test prescribers' DDI knowledge and perceived usefulness of DDI information sources, and to examine factors that may be associated with prescribers' DDI knowledge. METHODS: Data were obtained from a US national mail survey sent to 12,500 prescribers. The survey instrument included 14 drug-drug pairs that tested prescribers' ability to recognize clinically important DDIs and five 5-point Likert scaletype questions that assessed prescribers' perceived usefulness of DDI information provided by various sources. The knowledge and usefulness questions were examined via Rasch dichotomous and rating scale models, respectively. Regression analysis was used to examine factors related to prescribers' DDI knowledge scores which were derived from Rasch analysis. RESULTS: None hundred fifty completed questionnaires were received. Rasch analysis of knowledge and usefulness items revealed satisfactory model-data fit (infit mean square Ϲ 1.5 and outfit mean square
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